CDNA
CareDx, Inc.
$21.95
-1.35%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusBuy (62%)
Inst. Holders8 funds
Inst. Value$118.3M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 5S
Insider Net $-$578.7K
SEC Reports5
Recent Activity
Jun 6, 2026
Insider
Novack Jeffrey Adam sold 1,292 shares
Secretary and General Counsel @ $21.95 ($28.4K)
Jun 5, 2026
SEC
CareDx filed a DEFA14A supplementing its 2026 proxy statement to clarify the calculation of the 2025 cash bonus program
DEFA14A — Impact 2/10
Jun 4, 2026
short_volume
Short Volume: CDNA — 77.2% short (0.6M / 0.8M)
Short: 593,625 | Exempt: 20 | TRF Vol: 769,130 | Short Ratio: 77.2% | Off-exchange volume (dark pool
May 15, 2026
Insider
TORRES ARTHUR A sold 6,484 shares
Director @ $19.89 ($129.0K)
May 14, 2026
Insider
TORRES ARTHUR A sold 4,086 shares
Director @ $20.97 ($85.7K)
Apr 28, 2026
SEC
CareDx filed an automatic shelf registration (S-3ASR) on April 28, 2026, concurrently with the announcement of its Q1 20
S-3ASR — Impact 5/10
Apr 16, 2026
SEC
CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing se
8-K — Impact 8/10
Inst.
FMR LLC — ADD
209,419 shares ($3.9M)
Price Targets
$25.80
+13.4% upside
Buy
Current $22.75
Low $21.00
Median $26.00
High $28.00
5 analysts
$21.00
$28.00
Analyst Ratings
5Strong Buy
3Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 29, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Feb 26, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.23 ▲ +34.9% | $0.20 — $0.27 | 132% YoY | 5 |
| Next Q | $0.19 ▲ +1.1% | $0.17 — $0.21 | -33% YoY | 5 |
| Current FY | $0.93 ▲ +34.2% | $0.88 — $1.02 | 61% YoY | 5 |
| Next FY | $1.13 ▲ +3.8% | $0.96 — $1.34 | 21% YoY | 5 |
Latest Reports
NEUTRAL
DEFA14A
2/10
CareDx filed a DEFA14A supplementing its 2026 proxy statement to clarify the calculation of the 2025 cash bonus program
Jun 5, 2026
NEUTRAL
S-3ASR
5/10
CareDx filed an automatic shelf registration (S-3ASR) on April 28, 2026, concurrently with the announcement of its Q1 20
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $64.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $20.8M | — |
| MORGAN STANLEY | $10.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.9M | NEW |
| BANK OF AMERICA CORP | $6.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 6, 2026 | Novack Jeffrey | F | $28.4K |
| May 15, 2026 | TORRES ARTHUR | SELL | $129.0K |
| May 14, 2026 | TORRES ARTHUR | SELL | $85.7K |
| May 5, 2026 | Novack Jeffrey | SELL | $55.6K |
| May 1, 2026 | Novack Jeffrey | F | $61.8K |
8 institutional holders with $118.3M total value (6,280,654 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,428,252 | $64.6M | 54.6% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,105,198 | $20.8M | 17.6% | — |
| 3 | MORGAN STANLEY | 541,522 | $10.2M | 8.6% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 525,009 | $9.9M | 8.4% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 324,825 | $6.1M | 5.2% | — |
| 6 | FMR LLC | 209,419 | $3.9M | 3.3% | ADD +34.6% |
| 7 | TWO SIGMA INVESTMENTS, LP | 89,300 | $1.7M | 1.4% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 57,129 | $1.1M | 0.9% | ADD +70.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 155,616 | 209,419 | +34.6% | $3.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 89,300 | — | $1.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 33,584 | 57,129 | +70.1% | $1.1M | 2025-Q4 |
| FMR LLC | DOUBLED | 4,211 | 155,616 | +3595.5% | $2.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 156,614 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 321,906 | 156,614 | -51.3% | $3.1M | 2025-Q2 |
| UBS Group AG | TRIM | 262,986 | 126,215 | -52.0% | $2.5M | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 92,304 | 4,211 | -95.4% | $82.3K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 535,544 | 814,612 | +52.1% | $14.5M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 468,836 | 321,906 | -31.3% | $5.7M | 2025-Q1 |
| UBS Group AG | ADD | 158,314 | 262,986 | +66.1% | $4.7M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 22,675 | 29,760 | +31.2% | $637.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 499,480 | — | $15.6M | 2024-Q3 |
7 unique insiders with 5 transactions. Net insider value: -$578.7K ($0.00 bought, $578.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 6, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | F | 1,292 | $21.95 | $28.4K |
| May 15, 2026 | TORRES ARTHUR A | Director | SELL | 6,484 | $19.89 | $129.0K |
| May 14, 2026 | TORRES ARTHUR A | Director | SELL | 4,086 | $20.97 | $85.7K |
| May 5, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 2,688 | $20.68 | $55.6K |
| May 1, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | F | 2,873 | $21.50 | $61.8K |
| Apr 20, 2026 | Kennedy Keith | CFO & COO | A | 24,134 | $0.00 | $0.00 |
| Apr 16, 2026 | Hanna John Walter JR | President and CEO | SELL | 10,282 | $21.12 | $217.2K |
| Apr 15, 2026 | Hanna John Walter JR | President and CEO | F | 62,049 | $17.57 | $1.1M |
| Apr 6, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | F | 1,892 | $17.82 | $33.7K |
| Apr 2, 2026 | Goldberg Michael | Director | A | 1,981 | $0.00 | $0.00 |
| Apr 1, 2026 | Kennedy Keith | CFO & COO | F | 11,725 | $17.87 | $209.5K |
| Apr 1, 2026 | Meng Jessica | Chief Commercial Officer | F | 7,386 | $17.87 | $132.0K |
| Apr 1, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | F | 3,987 | $17.87 | $71.2K |
| Apr 1, 2026 | Hanna John Walter JR | President and CEO | F | 35,037 | $17.87 | $626.1K |
| Mar 31, 2026 | Goldberg Michael | Director | M | 5,255 | $0.00 | $0.00 |
| Mar 31, 2026 | Goldberg Michael | Director | M | 5,255 | $5.02 | $26.4K |
| Mar 31, 2026 | Goldberg Michael | Director | M | 11,500 | $0.00 | $0.00 |
| Feb 3, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 4,441 | $20.56 | $91.3K |
| Feb 2, 2026 | Kennedy Keith | Chief Operating Officer | A | 60,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Kennedy Keith | Chief Operating Officer | F | 4,644 | $20.42 | $94.8K |
| Feb 2, 2026 | Meng Jessica | Chief Commercial Officer | A | 60,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Meng Jessica | Chief Commercial Officer | F | 4,430 | $20.42 | $90.5K |
| Feb 2, 2026 | SMITH NATHAN | Chief Financial Officer | A | 33,000 | $0.00 | $0.00 |
| Feb 2, 2026 | SMITH NATHAN | Chief Financial Officer | F | 3,859 | $20.42 | $78.8K |
| Feb 2, 2026 | Hanna John Walter JR | President and CEO | A | 162,500 | $0.00 | $0.00 |
| Feb 2, 2026 | Hanna John Walter JR | President and CEO | F | 13,694 | $20.42 | $279.6K |
| Feb 2, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | A | 33,000 | $0.00 | $0.00 |
| Feb 2, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | F | 2,492 | $20.42 | $50.9K |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 6.0/10.
NEUTRAL
DEFA14A
2/10
CareDx filed a DEFA14A supplementing its 2026 proxy statement to clarify the calculation of the 2025
Jun 5, 2026
NEUTRAL
S-3ASR
5/10
CareDx filed an automatic shelf registration (S-3ASR) on April 28, 2026, concurrently with the annou
Apr 28, 2026
BULLISH
8-K
8/10
CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focu
Apr 16, 2026
BULLISH
8-K/A
8/10
CareDx reported strong 2025 financial results with 14% year-over-year revenue growth to $380 million
Feb 26, 2026
BULLISH
8-K
7/10
CareDx reported strong Q4 and full-year 2025 financial results with 25% YoY revenue growth in Q4 and
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (62% buy). Based on 13 analysts: 5 strong buy, 3 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$25.80 mean target
+13.4% upside
Buy (2.14)
$21.00 Low
$28.00 High
| Metric | Value |
|---|---|
| Current Price | $22.75 |
| Target Low | $21.00 |
| Target Mean | $25.80 |
| Target Median | $26.00 |
| Target High | $28.00 |
| # Analysts | 5 |
| Recommendation | Buy (2.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.23 | $0.20 | $0.27 | 132.0% | +34.9% | 1↑ 0↓ | $0.1B | 31.6% | 5 |
| Next Q 2026-09-30 |
$0.19 | $0.17 | $0.21 | -32.9% | +1.1% | — | $0.1B | 11.4% | 5 |
| Current FY 2026-12-31 |
$0.93 | $0.88 | $1.02 | 61.0% | +34.2% | — | $0.5B | 20.0% | 5 |
| Next FY 2027-12-31 |
$1.13 | $0.96 | $1.34 | 21.4% | +3.8% | — | $0.5B | 5.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.232 | |
| 7d ago | $0.232 | |
| 30d ago | $0.172 | +0.060 |
| 60d ago | $0.173 | +0.059 |
| 90d ago | $0.173 | +0.059 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 29, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 15, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 3 | 5 | 0 | 0 | 62% | |
| May 1, 2026 | 5 | 4 | 5 | 0 | 0 | 64% | |
| Apr 1, 2026 | 5 | 4 | 6 | 0 | 0 | 60% | |
| Mar 1, 2026 | 5 | 4 | 6 | 0 | 0 | 60% | |
| Feb 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% | |
| Jan 1, 2026 | 5 | 5 | 5 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
short_volume
Short Volume: CDNA — 77.2% short (0.6M / 0.8M)
Short: 593,625 | Exempt: 20 | TRF Vol: 769,130 | Short Ratio: 77.2% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: CDNA — 62.4% short (0.4M / 0.6M)
Short: 400,088 | Exempt: 11,849 | TRF Vol: 640,664 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
earnings_calendar
CDNA Q1 2026 Earnings After Market Close — 2026-04-28
Feb 24, 2026
earnings_calendar
CDNA Q4 2025 Earnings After Market Close — 2026-02-24